Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has issued an update.
Shandong Xinhua Pharmaceutical Company Limited has announced that it has received the Drug Registration Certificate for its Bisoprolol Fumarate Tablets from the National Medical Products Administration. This approval marks a significant step for the company in expanding its product offerings in the prescription drug market, potentially enhancing its market position and stakeholder value.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in the People’s Republic of China. It specializes in the production of various pharmaceutical products, including prescription drugs, with a focus on domestic production.
Average Trading Volume: 5,539,319
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.97B
For detailed information about 0719 stock, go to TipRanks’ Stock Analysis page.